KOREA PHARMA Completes 15B KRW 5th Convertible Bond Issuance... Conversion Price (10,782 KRW) Above Current Price (10,030 KRW), Capping Near-Term Dilution Risk but Long-Term Overhang Remains
KOREA PHARMA completed the issuance of the 5th unsecured private convertible bond worth 15 billion KRW on May 28, 2026, as decided by the board on May 20, 2026. The terms are identical to the previous disclosure.
The conversion price is set at 10,782 KRW, reflecting a 2.8% premium over the reference stock price (10,490 KRW) one day before the decision. However, the current stock price (10,030 KRW) is 7.0% below the conversion price, making the CB out-of-the-money with low immediate conversion likelihood.
Upon conversion, 1,391,207 new shares would be issued, representing 11.31% of the current outstanding shares (10,906,701). Combined with existing CBs, total potential dilution reaches 22.40%, posing long-term shareholder value dilution risk.
All proceeds will be used as operating funds for R&D and productivity enhancement: 2.5 billion KRW in 2026, 2.5 billion in 2027, and 10 billion from 2028 onwards.
[AI Comprehensive Analysis]In the short term, the conversion price above the current price limits dilution risk. However, the issuance size equals 13.7% of market cap, and future conversion if the stock rises remains an overhang. The use of funds for growth investment is positive, but considering the dilution magnitude relative to enterprise value, the overall impact is slightly negative rather than neutral.
KOSDAQ Filing Information
Filing: Securities Issuance Result (Voluntary Disclosure)